sars-cov-2 ad5
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
2
Earliest trial started May 25, 2021 (NCT04892459)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04952727 | Phase 4 | Aug 26, 2021 | Government of China, Tianjin Cansino Biotechnology Inc |
| NCT04892459 | Phase 4 | May 25, 2021 | Government of China, Tianjin Cansino Biotechnology Inc |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 2 | 1 | 2021 |
| Tianjin Cansino Biotechnology Inc | For profit | 2 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1